CXCL12 and atherosclerosis: found that CXCL12 interacted with CXCR4 to activate the GSK‐3β/β‐catenin/TCF21 pathway, thereby reducing plasma HDL‐C levels and the efficacy of reverse cholesterol transport, inhibiting ABCA1‐dependent cholesterol efflux from macrophages, and exacerbating atherosclerosis.